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Background. Benign prostatic hyperplasia (BPH) pharmacological treatment may promote a decrease in prostate vascularization
and bladder neck relaxation with theoretical improvement in prostate biopsy morbidity, though never explored in the literature.
Methods. Among 242 consecutive unselected patients who underwent prostate biopsy, after excluding those with history of prostate
biopsy/surgery or usingmedications not for BPH, we studied 190 patients. On the 15th day after procedure patients were questioned
about symptoms lasting over aweek and classified according to pharmacological BPH treatment.Results.Thirty-three patients (17%)
were using alpha-blocker exclusively, five (3%) 5-alpha-reductase inhibitor exclusively, twelve (6%) patients used bothmedications,
and 140 (74%) patients used none. There was no difference in regard to age among groups (𝑃 = 0.5). Postbiopsy adverse effects
occurred as follows: hematuria 96 (50%), hematospermia 53 (28%), hematochezia 22 (12%), urethrorrhagia 19 (10%), fever 5
(3%), and pain 20 (10%). There was a significant negative correlation between postbiopsy hematuria and BPH pharmacological
treatment with stronger correlation for combined use of 5-alpha-reductase inhibitor and alpha-blocker over 6months (𝑃 = 0.0027).
Conclusion. BPHpharmacological treatment,mainly combined for at least 6months seems to protect against prostate biopsy adverse
effects. Future studies are necessary to confirm our novel results.
1. Introduction
Biopsy of the prostate to diagnose or exclude cancer is
performed nearly one million times annually in the USA
[1]. The main tests used for early prostate cancer detection
are (1) digital rectum examination (DRE) and (2) prostate-
specific antigen (PSA); the first is a subjective and examiner-
dependent test, and the second is not always correlated with
prostate malignancy [2–4], so the method of choice for a
conclusive diagnosis is transrectal ultrasound guided prostate
biopsy, with a rising concern regarding its collateral effects
and complications nowadays [5].
Prostate biopsy may be associated with a significant rate
of adverse effects in over 80% of the patients [6], such as pain,
lower urinary tract symptoms, urinary retention, erectile
dysfunction, and more frequently bleeding and infection [7].
Pharmacological treatment for benign prostate hyperpla-
sia (BPH) classically comprises two drug classes: 5-alpha-
reductase inhibitors and alpha-blockers that may promote a
decrease in prostate tissue vascularization [8–10] and bladder
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neck and prostate relaxation [11], which might lead to a
theoretical improvement in prostate biopsy morbidity and
complications, although never tested before in the literature.
This study aims to evaluate prostate transrectal biopsy
adverse effects in patients after pharmacological BPH treat-
ment compared to patients not under BPH treatment.
2. Methods
2.1. Population. This study was performed in accordance
with institutional ethical guidelines, based on good clinical
practice. We retrospectively studied a prospectively collected
database of 242 unselected and consecutive male adults who
underwent transrectal ultrasound guided prostate biopsy in a
general urologic clinic from a community hospital in 2012.
2.2. Biopsy Indications. All patients with a PSA value greater
than 4.0 ng/mL or suspicious DRE were considered eligible
for prostate biopsy [12].
2.3. Exclusion Criteria. Patients with previous history of
prostate biopsy or prostatic surgery, those taking additional
medications, and those who presented adverse effects due to
BPH pharmacological treatment or undertreatment for less
than 6 months were excluded from analysis (𝑛 = 52).
2.4. Prostate Biopsy. All patients underwent 12-core transrec-
tal ultrasound guided prostate biopsy performed by a single
urologist, using a side-notch cutting biopsy needle (18G, 19-
mm stroke length). The biopsies were performed following
rectal enema and local anesthesia 10mL of lidocaine 2% in
the neurovascular bundle bilaterally (5mL each side) via a
6.5 Hz probe ultrasound (Logiq 100; GE Medical Systems,
Milwaukee, WI).
The primary peripheral zone biopsy localizations were
apical, middle, and base, being 2 cores each zone: one
paramedian and another lateral [13].When there was a nodule
on digital rectal prostate examination or a hypoechoic area
was detected through ultrasound, 02 additional biopsy cores
were taken from these sites [14].
2.5. Previous Pharmacological Treatment for BPH. Patients
were classified according to the chronic use of 5-alpha-
reductase inhibitor (finasteride 5mg/day or dutasteride
0.5mg/day) and/or alpha-blockers (doxazosin 4mg/day or
tamsulosin 0.4mg/day) for at least 6 months.
2.6. Analysis of Adverse Effects. According to the local institu-
tional surveillance protocol for adverse effects, on the 15th day
after the biopsy, patients were interviewed and questioned
regarding possible biopsy adverse effects lasting more than
one week after the procedure such as hematuria, hematosper-
mia, hematochezia, and urethrorrhagia. Additionally, fever
after procedure was defined as elevation of body temperature
above 37.5∘C (99.5∘F), at least one episode. Possible answers
were Yes or No.
A: Post procedure pain was graded based on a visual
analog scale (VAS; 0 = none to 10 = worst pain) and those
patients referring to VAS ≥ 5 24 h after the procedure were
classified as clinically significant pain.
2.7. Statistics. Variables were expressed as mean ± standard
deviation (range). Student 𝑡- and Fisher tests were used when
indicated and two-sided 𝑃 < 0.05was considered significant.
3. Results
Among patients prospectively analyzed (𝑛 = 190), thirty-
three patients (17%) were using alpha-blocker exclusively,
mean age 62 ± 8 (39–89) years; five (3%) patients used 5-
alpha-reductase inhibitor exclusively, mean age 64 ± 9 (45–
72); twelve (6%) patients used both medications, mean age
68±6 (58–79) years; and 140 (74%) patients used none, mean
age 63 ± 9 (43–87) years. There was no difference in regard to
age among groups (𝑃 = 0.5).
Postbiopsy adverse effects occurred as follows: hematuria
96 (50%), hematospermia 53 (28%), hematochezia 22 (12%),
and urethrorrhagia 19 (10%). Fever occurred in 5 (3%) and
significant pain in 20 (10%). No patient presented severe
adverse effect such as sepsis or fever for more than 72 h and
there was no hospitalization need in the reported series.
There was a significant negative correlation between
postbiopsy hematuria and previous use of medications for
BPH (𝑃 = 0.01), being the stronger correlation for those
under combined use of 5-alpha-reductase inhibitor and
alpha-blocker for over 6 months (𝑃 = 0.0027) (Table 1).
4. Discussion
Our results are hypothesis generating and show for the
first time in the literature that BPH pharmacological treat-
ment and mainly the combined therapy of 5-alpha-reductase
inhibitors and alpha-blockers for at least 6 months may
protect against hematuria after prostate biopsy.
The pharmacological treatment of BPH, mainly the
5-alpha-reductase inhibitors, may reduce the prostate
microvessel density, which could, theoretically, decrease the
rate of hemorrhagic symptoms after prostate biopsy [8, 15].
Alpha-blockers acting as bladder neck and prostate relax-
ants can also potentially impact prostate biopsy adverse
effects. Specifically regarding hemorrhagic adverse effects
that we showed to be the most frequent, blockade of alpha-
adrenergic receptors reduces the sympathetic tone of blood
vessels resulting in decreasing vascular resistance, reducing
blood pressure, and eventuallyminimizing local hemorrhagic
adverse effects.
Additionally, Keledjian et al. studying human prostate
showed incremental apoptosis with decreased cell prolifera-
tion, microvessel density, vascular endothelial growth factor
(VEGF), and prostate specific antigen (PSA) immunoreac-
tivities in patients under alpha-blockers [10]. However, the
present study is the very first to consider these supposed
mechanisms in the prostate biopsy scenario, warranting
further analyses.
Prostate biopsy is generally well tolerated, with a low
risk of major complications such as infection and sepsis.
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Hematuria 82 (59%) 12 (36%) 0.01 1 (20%) 0.02 1 (8%) 0.003
Hematospermia 42 (30%) 6 (18%) 0.2 3 (60%) 0.1 2 (17%) 0.5
Hematochezia 16 (11%) 4 (12%) 1 1 (20%) 0.5 1 (8%) 1
Urethrorrhagia 12 (9%) 6 (18%) 0.1 0 (zero) 1 1 (8%) 1
Fever 4 (3%) 1 (3%) 1 0 (zero) 1 0 (zero) 1
Pain∗∗ 16 (11%) 2 (6%) 0.5 1 (20%) 0.5 1 (8%) 1
Control: patients not using any medication (control/reference). Group 1: patients using alpha-blockers, exclusively. Group 2: patients using 5-alpha-reductase,
exclusively. Group 3: patients using both medications. 𝑃 value ≤0.05 was considered significant (bold). ∗Lasting more than one week after the procedure.
∗∗Visual analog scale (VAS) ≥5, 24 h after the procedure.
Minor complications also called adverse effects such as pain
and bleeding are frequent and represented by hematuria,
hematospermia, and hematochezia [16, 17]. Our results
showed an occurrence of fever in only 3% of the patients and
hemorrhagic adverse effects in over 80%.
Prostate biopsy causes important pain, discomfort, and
anxiety in most patients, mainly during the procedure, but
there are scarce data dealing with pain in the days after the
biopsy [18]. Our results show that only 10% of all patients had
significant pain on subsequent days.
Kravchick et al. showed that 6 weeks of dutasteride
treatment might reduce prostate tissue vascularity in the
periurethral area proximal to the verumontanum [8]. Thus
it was logical to apply this condition into a surgical situation,
as did a few authors by analyzing the postoperative bleeding
in patients using 5-alpha-reductase inhibitors. They showed
that pretreatment with dutasteride for 4 to 6 weeks before
transurethral resection of the prostate reduces the surgical
bleeding considerably [19, 20].
Other authors focused on the postoperative complica-
tions. Hahn et al. showed no significant reductions in post-
operative bleeding among patients taking 5-alpha-reductase
for 2 weeks before transurethral resection of the prostate
[21]. In a similar study, Arratia-Maqueo et al. also showed
no significant reductions in postoperative bleeding among
patients taking the same medicine for a longer time period
of 4 weeks [22].
Whereas the rational for 5-alpha-reductase inhibitors
impacting adverse effects has been explored in the context of
prostate transurethral resection (TUR), alpha-blockers acting
as bladder neck and prostate relaxants can also potentially
impact prostate manipulation adverse effects.
While controversial, the effect of 5-alpha-reductase
inhibitors was never proposed in the setting of prostate
biopsy and the impact of alpha-blockers was underexplored
even in the TUR scenario. The current study is the first in
the literature to measure the impact of 5-alpha-reductase
inhibitors and alpha-blockers on prostate biopsy adverse
effects.
Although based on a prospectively collected database
with unprecedented original rational, the study has some
limitations.
First, a relatively small number of patients were compared
after grouping, impeding subgroup analyses of different
drugs in the same class (i.e., finasteride versus dutasteride
and doxazosin versus tamsulosin), even though of minor
importance. Second, the grade of low urinary tract symptoms
(LUTS) and prostate volumewere notmeasured in this series,
factors that certainly determined pharmacological treatment
indication.
Additionally, patients under medications for less than 6
months were excluded and adverse effects were graded as
lasting over a week or not, an arbitrary criterion, although
objective and easy to measure.
Last but not least, this study design although important
as hypothesis generating cannot precisely distinguish if dif-
ferences observed are regarding medicines utilized and their
potential effects or regarding BPH/LUTS that culminated
with BPH treatment.
Future studies including larger series of patients with a
wide range of LUTS and prostate volumes, with randomized
and placebo controlled design, assessing the impact of spe-
cificmonotherapy, including additional information andwith
different BPH pharmacological treatment intervals (i.e., one,
three, six, twelve, and over months) and refining the adverse
effects grading criteria, are warranted to expand knowledge
regarding this underexplored issue.
5. Conclusions
In this preliminary original and hypothesis generating study,
BPH pharmacological treatment, mainly combined use of
5-alpha-reductase inhibitors and alpha-blockers for at least
6 months, might protect against hematuria after prostate
biopsy. Future larger studies must be conducted to confirm
our innovative results.
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